Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Up 213.1% in January

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 61,344 shares, an increase of 213.1% from the January 15th total of 19,594 shares. Currently, 9.0% of the shares of the stock are sold short. Based on an average trading volume of 506,631 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 506,631 shares, the short-interest ratio is presently 0.1 days. Currently, 9.0% of the shares of the stock are sold short.

Biodexa Pharmaceuticals Stock Down 0.9%

Biodexa Pharmaceuticals stock opened at $1.08 on Friday. Biodexa Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $47.79. The company has a 50 day moving average price of $2.79 and a 200 day moving average price of $5.08.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BDRX. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.